Polymeric treatment compositions

Patent metadata

Field	Value
Publication number	US-11998563-B2
Application number	US-202217744192-A
Country	US
Kind code	B2
Filing date	May 13, 2022
Priority date	Jun 14, 2012
Publication date	Jun 4, 2024
Grant date	Jun 4, 2024

Abstract

Compositions are described comprising a polymer; a non-physiological pH solution; and a visualization agent; wherein the polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

First claim

We claim:

1. A composition comprising:
a biocompatible polymer comprising:
a first monomer wherein the first monomer is t-butyl acrylate;
a second monomer wherein the second monomer is an alkyl acrylate comprising a hydroxyl group; and
a third monomer wherein the third monomer is hydroxyethyl methacrylate;

a pH-sensitive component, wherein the pH-sensitive component is selected from aminopropyl methacrylamide, aminoethyl methacrylamide, N-(3-methylpyridine)acrylamide, N-(2-(4-aminophenyl)ethyl)acrylamide, N-(4-aminobenzyl)acrylamide, N-(2-(4-imidazolyl)ethyl)acrylamide, derivatives thereof, and combinations thereof;
an aqueous solution with a non-physiological pH; and
a visualization agent;

wherein the biocompatible polymer is soluble in the aqueous solution and insoluble at a physiological pH at a treatment site.

2. The composition of claim 1 , wherein the visualization agent is a particulate.

3. The composition of claim 1 , wherein the visualization agent has a concentration of about 5% w/w to about 65% w/w.

4. The composition of claim 1 , wherein the visualization agent is barium sulfate or tantalum.

5. The composition of claim 1 , wherein the non-physiological pH solution is water.

6. The composition of claim 1 , wherein the non-physiological pH solution has a pH of less than about 6.

7. The composition of claim 1 , wherein the biocompatible polymer has a concentration of about 1% w/w to about 35% w/w.

8. The composition of claim 1 , wherein the biocompatible polymer further includes a polymerization initiator.

9. The composition of claim 8 , wherein the polymerization initiator is azobisisobutyronitrile.

10. The composition of claim 8 , wherein the polymerization initiator has a concentration of about 0.25% w/w to about 2% w/w.

11. The composition of claim 1 , wherein the pH-sensitive component is aminopropyl methacrylamide.

Assignees

• Microvention Inc

Inventors

• Cruise Gregory M
• Constant Michael J
• Garretson Joshua

Classifications

• A61K31/785 Primary

  Polymers containing nitrogen · CPC title

• A61K9/0024

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title

• A61K31/78

  of acrylic acid or derivatives thereof · CPC title

• A61L24/0089

  containing inorganic fillers not covered by groups A61L24/0078 or A61L24/0084 · CPC title

• A61L24/046

  obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds (A61L24/043 takes precedence) · CPC title